DiscoveryBioMed, Inc. (DBM) is excited to announce that The Sage Group is actively representing the company and our multiple assets in M&A partnering conversations.
“We met Bill Mason, Wayne Pambianchi, and other principals for The Sage Group in BIO Digital, the 2020 virtual partnering event. They have deep experience in the life sciences and biotechnology sector and principals covering virtually every continent and market”, explained Dr. Erik Schwiebert, DBM’s Founder and Director. “DBM has completed 12 years of business and we are currently in our 13th year. Our CRO services business is growing and has a positive trajectory, we have multiple and different preclinical lead small molecule assets with a focus in the Human Renal Diseases landscape, and we have identified a unique niche in discovering, validating and/or profiling new small molecules or existing lead therapeutic assets in disease-relevant and biologically-relevant human cells from a plethora of different human tissues.”
The Sage Group has Information Memoranda for both sides of the DBM business and they will be representing DBM at BIO Europe at the end of October.